Taken together, our results demonstrate, for the first time, that overexpression of xCT, a cisplatin resistance associated marker, in CDC tumors, and suggest that xCT targeted combination therapies may be beneficial to CDC patients. This evidence concerns the gene SLC7A11 and collecting duct carcinoma.